| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882930 | Clinical Lymphoma Myeloma and Leukemia | 2014 | 7 Pages |
Abstract
Oxaliplatin, cytarabine, and fludarabine therapy had antileukemic activity in patients with poor-risk AML, but it was associated with toxicity. Different schedules and doses may be better tolerated.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Apostolia Maria Tsimberidou, Michael J. Keating, Elias J. Jabbour, Farhad Ravandi-Kashani, Susan O'Brien, Elihu Estey, Neby Bekele, William K. Jr., Hagop Kantarjian, Gautam Borthakur,